FDA Investigator Roy R Rinc

Roy R Rinc has inspections in 10 countries as of 19 Sep 2023. Roy R Rinc has collaborated with a combinined 3445 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
65
Last Inspection Date:
19 Sep 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
Italy, United States of America, France, Slovakia, Germany, Japan, Ireland, Denmark, United Kingdom of Great Britain and Northern Ireland, Switzerland
Co-Investigator(s):
Adam R Cooke, Ademola O Daramola, Alexander B Anderson, Ana Delp Cintron, Ana P Barido, Anabel Veiga, Andrea A Branche, Anh M Lac, Anita R Michael, Ariel Cruz Figueroa, Arsen Karapetyan, Azza Talaat, Barbara J Rincon, Barbara M Frazier, Bill Tacket, Jr, Brian D Nicholson, Brian S Keefer, Brittani N Franklin, Brooke K Higgins, Brooke K Seeman, Burnell M Henry, Camerson E Moore, Carl A Huffman, III, Caroline Strasinger, CDR Ileana Barreto Pettit, Charles D Brown, Cheryl A Clausen, Chiaochun J Wang, Christopher T Middendorf, Christopher T Smith, Christos G Tsingelis, Claire M Minden, Clara E Santiago, Craig A Garmendia, Dale A Nyberg, Dandan Wang, PhD, Darren S Brown, Dawn M Mccabe, Denise Connelly, Dennis Cantellops Paite, Diane Cvan Leeuwen, Don H Bark, PhD, Donald L Lech, Dr. Carmelo Rosa, Dr. Sriram Subramaniam, PhD, Dyvette Arline, Edwards, Eric W Anderson, Erik W Koester, Erin L Mcfiren, Fabian Nchaparro Rodriguez, Felix Maldonado, Frederick L Fricke, Gajendiran Mahadevan, PhD, Gerald B Seaborn, Jr, Gerald N Mcgirl, DDS, German Rivera, Heather M Bullock, Hunt, James C Maclaughlin, James I Giefer, James L Dunnie, Jr, James M Kewley, James M Mason, James P Mcevoy, James P Stumpff, Jay T Wong, Jeffrey W Shrifter, DPM, Jennifer D Hollstrom, Jennifer L Huntington, Jennifer Lalama, Jennifer M Donzanti, Jennifer M Menendez, Jeremy W Rotton, Jessica L Pressley, Joanne E King, Joe X Phillips, Joey V Quitania, Jogy George, John J Bernal, John W Banks, Jorge L Lajara, Jose Acruz Gonzalez, Jose E Melendez, DDC, Joseph X Phillips, Joshua P Wireman, Justin A Boyd, Karen M Rodriguez, Karen Takahashi, Karl D Hezel, Kathleen B Swat, Kathleen M Sinninger, Kathy E Craven, Kathy E Noe, Kayla V Sprague, Kendra A Biddick, Kevin D Kallander, Kevin T Nguyen, Kham Phommachanh, Khunnathee Stoner, Kim Lthomas Cruse, LCDR Chad N Thompson, LCDR Debra Emerson, Leyden Guerrero, Libia M Lugo, Lillian Mcolon Mcknight, Linda Thai, Lisa M Bellows, Lisa R Whitt, Lissette Paiz, Lourdes Andujar, LT Richard A Lyght, Lucas B Leake, Luis A Dasta, Luz I Collado, Marc Balzarini, Marcellinus D Dordunoo, Maria V Price, Marie F Morin, Martin F Muckenfuss, Martin K Yau, PhD, Maya M Davis, Meisha R Sampson, Merril E Racke, Merril R Racke, Michael A Taylor, Michael D Skelly, PhD, Michael E Maselli, Michael F Skelly, PhD, Michael P Sheehan, Michael Shanks, MS, Michele L Obert, Miguel A Martinez, Mihaly S Ligmond, Minh D Phan, Monica E Caphart, Mra B Kamberem, Mra Davism, Mra Mcculloughj, Nicole M Bell, Noreen Muniz, Parul M Patel, Patrick D Stone, MS, Patty P Kaewussdangkul, Paul L Figarole, Jr, Pratik S Upadhyay, DDC, Rachel A Gomez, Rachel A Peters, Raymond T Oji, Reba A Gates, Rebecca Rodriguez, Rina Bhikha, Robert C Coleman, Robert D Tollefsen, Robert J Ham, Robert Sharpnack, Ronald Ifraimov, Rozelle G Smith, Russell J Glapion, Saleem A Akhtar, Sally Gopaul, Salvatore N Randazzo, Samantha J Bradley, Sandra A Hughes, Sangeeta M Khurana, PhD, Sarah E Mcmullen, Sarah Ibrahim, Sena G Dissmeyer, Sharon Giamberini, Shirley J Berryman, Simone E Pitts, State Agency, Stephanie D Crockett, Stephen D Brown, Steven Eastham, Steven M Weinman, Susan M Corrales, Susan M Turcovski, Susan W Ting, Taichun Qin, PhD, Teresa I Navas, Terrance L Thomas, Thomas J Arista, Tiffani D Wilson, Tina M Pawlowski, Truong Xuan Nguyen (Andy), Victor Spanioli, Vlada Matusovsky, Wayne E Seifert, Xiaoping Guan, Yasamin Ameri, Yumi J Hiramine, Zachary A Bogorad

Roy R Rinc's Documents

Publish Date Document Type Title
August, 2000 FDA 483 Watson Laboratories, Inc. - Form 483, 2000-08-17
April, 2004 FDA 483 NUVISAN GmbH - Form 483, 2004-04-23
September, 2001 EIR Bio-Nucleonics Inc. - EIR, 2001-09-26
May, 2001 FDA 483 Watson Laboratories, Inc. - Form 483, 2001-05-18
November, 2001 EIR Drs. Giampietro Nordera / Marco Bateni - EIR, 2002-01-09
October, 2002 FDA 483 Response F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. - Form 483R, 2002-10-16
April, 2002 FDA 483 Sameer K. Mehta, M.D. - Form 483, 2002-04-02
October, 2002 EIR Instituto Biochimico Italiano Giovanni Lorenzini SpA - EIR, 2002-10-30
February, 2000 FDA 483 Response Watson Laboratories, Inc. - Form 483R, 2000-03-22
February, 2003 EIR USpharma Ltd - EIR, 2003-02-05
October, 2000 EIR F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. - EIR, 2000-10-18
November, 2001 FDA 483 Drs. Giampietro Nordera / Marco Bateni - Form 483, 2001-11-29
February, 2004 EIR Mylan Teoranta - EIR, 2004-02-04
December, 2004 FDA 483 Pure Source, LLC - Form 483, 2004-12-27
July, 2003 FDA 483 Noven Pharmaceuticals, Inc. - Form 483, 2003-06-25
June, 2000 FDA 483 Nippon Kayaku Co, Ltd. - Form 483, 2000-06-30
January, 2002 EIR Montoro, Rafael T. MD - EIR, 2002-01-22
June, 2000 EIR Nippon Kayaku Co., Ltd. - EIR, 2000-06-30
April, 2002 EIR Sameer K. Mehta, M.D. - EIR, 2002-04-02
April, 2004 EIR NUVISAN GmbH - EIR, 2004-07-15
March, 2002 EIR Actavis Laboratories FL, Inc. - EIR, 2002-03-01
August, 2000 FDA 483 Response Watson Laboratories, Inc. - Form 483R, 2000-09-20
October, 2002 EIR F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. - EIR, 2002-10-16
January, 2001 EIR KOS Pharmaceuticals Inc - EIR, 2001-01-05
February, 2003 FDA 483 USpharma Ltd - Form 483, 2003-02-05
December, 2001 EIR Dr. Maria Francesca De Pandis - EIR, 2001-12-06
August, 2000 EIR Watson Laboratories, Inc. - EIR, 2000-08-17
October, 2000 FDA 483 Response F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. - Form 483R, 2001-01-03
May, 2001 EIR Watson Laboratories, Inc. - EIR, 2001-05-18
September, 2003 FDA 483 OHM PHARMA INC. - Form 483, 2003-09-29
February, 2004 FDA 483 Response Mylan Teoranta - Form 483R, 2004-02-11
March, 2001 EIR Catalent Germany Eberbach GmbH - EIR, 2001-04-20
October, 2000 FDA 483 Eli Lilly Italia S.p.A. - Form 483, 2000-10-25
February, 2004 FDA 483 Mylan Teoranta - Form 483, 2004-02-04
December, 2001 FDA 483 Dr. Maria Francesca De Pandis - Form 483, 2001-12-06
May, 2001 FDA 483 Response Watson Laboratories, Inc. - Form 483R, 2001-08-13
October, 2000 EIR Capua Bioservices S.p.A. - EIR, 2000-10-11
February, 2000 FDA 483 Watson Laboratories, Inc. - Form 483, 2000-02-04
March, 2002 FDA 483 Actavis Laboratories FL, Inc. - Form 483, 2002-03-01

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.


Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more